Betrixaban - Dosing and Renal Function Effects

CrCL FDA Recommended Dose for Prevention of VTE in Hospitalized, Medically Ill Patients AUC T 1/2
> 90 ml/min          

160mg x1 dose, then 80mg daily for 35-42 days

(80mg x1 dose, then 40mg daily for 35-42 days if using with concurrent p-GP inhibitors)

reference
  • 19-27 hrs per PI
  • 37 hrs per clinical pharmacology  studies
60-90 ml/min increase 1.89 x            
30-60 ml/min          increase 2.27 x
15-30 ml/min         80mg x1 dose, then 40mg daily for 35-42 days increase 2.63 x not reported
< 15 ml/min            Not recommended not reported